(Q44020440)

29 November 2017

title

The role of disodium pamidronate in the management of bone pain due to malignancy (English)

1 reference

29 November 2017

0 references

8

1 reference

29 November 2017

R Boffi

5

0 references

Ernesto Zecca

object named as

E Zecca

2

0 references

Cinzia Brunelli

object named as

C Brunelli

4

0 references

author name string

L Groff

1

1 reference

29 November 2017

F De Conno

3

1 reference

29 November 2017

C Panzeri

6

1 reference

29 November 2017

M Cazzaniga

7

1 reference

29 November 2017

language of work or name

1 reference

1 July 2001

1 reference

29 November 2017

1 reference

29 November 2017

volume

15

1 reference

29 November 2017

issue

4

1 reference

29 November 2017

page(s)

297-307

1 reference

Pain in far-advanced cancer

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Malignant bone pain: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Malignant bone pain: pathophysiology and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

The clinical course of bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Different doses of pamidronate in patients with painful osteolytic bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921601678320287

10.1191/026921601678320287

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference